Annual Current Liabilities
$8.90 M
-$5.59 M-38.59%
March 31, 2024
Summary
- As of February 8, 2025, SXTC annual total current liabilities is $8.90 million, with the most recent change of -$5.59 million (-38.59%) on March 31, 2024.
- During the last 3 years, SXTC annual current liabilities has fallen by -$9.68 million (-52.09%).
- SXTC annual current liabilities is now -52.09% below its all-time high of $18.58 million, reached on March 31, 2021.
Performance
SXTC Current Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Current Liabilities
$8.90 M
-$298.20 K-3.24%
March 31, 2024
Summary
- As of February 8, 2025, SXTC quarterly total current liabilities is $8.90 million, with the most recent change of -$298.20 thousand (-3.24%) on March 31, 2024.
- Over the past year, SXTC quarterly current liabilities has dropped by -$5.59 million (-38.59%).
- SXTC quarterly current liabilities is now -52.09% below its all-time high of $18.58 million, reached on March 31, 2021.
Performance
SXTC Quarterly Current Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Current Liabilities Formula
Current Liabilities = Accounts Payable + Short-Term Debt + Accrued Expenses + Other Current Liabilities
SXTC Current Liabilities Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -38.6% | -38.6% |
| 3 y3 years | -52.1% | -38.6% |
| 5 y5 years | +40.8% | -38.6% |
SXTC Current Liabilities Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -52.1% | at low | -48.0% | +22.1% |
| 5 y | 5-year | -52.1% | +40.8% | -52.1% | +61.7% |
| alltime | all time | -52.1% | +148.7% | -52.1% | +123.0% |
China SXT Pharmaceuticals Current Liabilities History
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2024 | $8.90 M(-38.6%) | $8.90 M(-3.2%) |
| Sep 2023 | - | $9.20 M(-36.5%) |
| Mar 2023 | $14.50 M(-15.3%) | $14.50 M(+98.8%) |
| Sep 2022 | - | $7.29 M(-57.4%) |
| Mar 2022 | $17.12 M(-7.8%) | $17.12 M(+92.8%) |
| Sep 2021 | - | $8.88 M(-52.2%) |
| Mar 2021 | $18.58 M | $18.58 M(+237.4%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2020 | - | $5.51 M(-55.1%) |
| Mar 2020 | $12.26 M(+94.0%) | $12.26 M(+13.9%) |
| Sep 2019 | - | $10.76 M(+70.3%) |
| Mar 2019 | $6.32 M(+44.6%) | $6.32 M(+58.4%) |
| Sep 2018 | - | $3.99 M(-8.7%) |
| Mar 2018 | $4.37 M(+22.2%) | $4.37 M |
| Mar 2017 | $3.58 M | - |
FAQ
- What is China SXT Pharmaceuticals annual total current liabilities?
- What is the all time high annual current liabilities for China SXT Pharmaceuticals?
- What is China SXT Pharmaceuticals annual current liabilities year-on-year change?
- What is China SXT Pharmaceuticals quarterly total current liabilities?
- What is the all time high quarterly current liabilities for China SXT Pharmaceuticals?
- What is China SXT Pharmaceuticals quarterly current liabilities year-on-year change?
What is China SXT Pharmaceuticals annual total current liabilities?
The current annual current liabilities of SXTC is $8.90 M
What is the all time high annual current liabilities for China SXT Pharmaceuticals?
China SXT Pharmaceuticals all-time high annual total current liabilities is $18.58 M
What is China SXT Pharmaceuticals annual current liabilities year-on-year change?
Over the past year, SXTC annual total current liabilities has changed by -$5.59 M (-38.59%)
What is China SXT Pharmaceuticals quarterly total current liabilities?
The current quarterly current liabilities of SXTC is $8.90 M
What is the all time high quarterly current liabilities for China SXT Pharmaceuticals?
China SXT Pharmaceuticals all-time high quarterly total current liabilities is $18.58 M
What is China SXT Pharmaceuticals quarterly current liabilities year-on-year change?
Over the past year, SXTC quarterly total current liabilities has changed by -$5.59 M (-38.59%)